New drug targeted for Kaposi’s sarcoma

A team of scientists from UCSF and colleagues have identified a new potential drug target for the herpes virus that causes Kaposi’s sarcoma. Their research reopens the possibility of using a class of drugs called protease inhibitors, against diseases ranging from cancer to Alzheimer's Disease. This research was published online in Nature Chemical Biology, July 26, 2009. The lead author is Tina Shahian, UCSF Graduate Group in Biochemistry and Molecular Biology. Authors from the UCSF School of Pharmacy, Department of Pharmaceutical Chemistry, are senior author Charles S. Craik, PhD, Gregory Lee, and Ana Lazic. Other authors are colleagues from St. Jude Children’s Research Hospital.

Full story

UCSF researchers identify new drug target for Kaposi’s Sarcoma

Research paper

Inhibition of a viral enzyme by a small-molecule dimer disruptor, Nature Chemical Biology, July 26, 2009

About the School: The UCSF School of Pharmacy is a premier graduate-level academic organization dedicated to improving health through precise therapeutics. It succeeds through innovative research, by educating PharmD health professional and PhD science students, and by caring for the therapeutics needs of patients while exploring innovative new models of patient care. The School was founded in 1872 as the first pharmacy school in the American West. It is an integral part of UC San Francisco, a leading university dedicated to promoting health worldwide.